Skip to main content

Table 2 Compliance loss thresholds for various price levels of generic risperidone at which staying on branded risperidone is cost-effective and dominant

From: A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss

Price reduction for generic risperidone (compared to branded price) Min. compl. loss for cost-effectiveness* Min. compl. loss for dominance
20% 2.8% 3.7%
30% 4.1% 5.5%
40% 5.2% 6.9%
50% 6.7% 8.8%
60% 7.9% 10.5%
  1. † Only applied to the three least intensive treatment settings
  2. *At a willingness to pay of €40,000 per QALY gained